Innospec (IOSP) Cash & Equivalents (2010 - 2026)

Innospec's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $289.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 3.57% year-over-year to $289.1 million; the TTM figure through Mar 2026 stood at $289.1 million (down 3.57% YoY), while the FY2025 annual figure was $292.5 million, up 1.14% from the prior year.
• Cash & Equivalents came in at $289.1 million for Q1 2026 at Innospec, down from $292.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $303.8 million in Q3 2024 to a low of $71.4 million in Q2 2022.
• A 5-year average of $215.9 million and a median of $240.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents decreased 24.36% in 2022 and surged 132.35% in 2023, its largest moves.
• Innospec's Cash & Equivalents stood at $147.1 million in 2022, then jumped by 38.48% to $203.7 million in 2023, then soared by 41.97% to $289.2 million in 2024, then rose by 1.14% to $292.5 million in 2025, then fell by 1.16% to $289.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $289.1 million, $292.5 million, and $270.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison